Experimental Treatment for High-Risk Pulmonary Nodules

Pembrolizumab in Treating Patients With High-Risk Pulmonary Nodules

This phase II trial studies how well pembrolizumab works in treating patients with high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the pre-malignant cells, and may inhibit the progression of pre-malignant cells into invasive cancer cells.

No pharmaceutical medication involved
Patients and healthy individuals accepted

Best Practice

Receive standard of care

Biological - Pembrolizumab

Given IV

Quality-of-Life Assessment

Ancillary studies

Randomized Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)